GRDX GridAI Technologies Corp.
Healthcare$4.58+0.00%OpenMarket Cap: $15.4M
As of 2026-05-26
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
0.33
P/S
448.86
EV/EBITDA
-2.67
DCF Value
$-1.68
FCF Yield
-35.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
-3398.9%
Operating Margin
-19540.0%
Net Margin
-18078.3%
ROE
-11.9%
ROA
-13.3%
ROIC
-18.2%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 null | $36.3K | $-3.1M | $— |
| FY null | $36.3K | $-6.6M | $— |
| Q3 null | $0.00 | $-1.2M | $— |
| Q2 null | $0.00 | $-998.3K | $— |
Analyst Ratings
View AllConsensus
Buy
Target (Consensus)
$—
Target (Median)
$—
Target Range
$— - $—
1 Strong Buy0 Buy0 Hold0 Sell0 Strong Sell
Trading Activity
Insider Trades
View AllBORKOWSKI EDWARDdirector
SellThu Jan 08
Uppal Manpreetdirector
SellMon Jan 05
Pursglove Geordan Garrettdirector
SellMon Jan 05
Skowron Annaofficer: Interim CFO
SellMon Dec 29
Skowron Annaofficer
SellMon Dec 29
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.39
GridAI Technologies Corp. is a clinical stage biopharmaceutical company, which engages in the research and development of targeted, non-systemic therapies for the treatment of patients with gastrointestinal diseases. Its pipeline includes Latiglutenase, Capeserod, Adrulipase, and Niclosamide. The company was founded on January 30, 2014 and is headquartered in Boca Raton, FL.